Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss

Stock News07-27 17:38

Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company between 1.18 billion yuan and 1.36 billion yuan. This represents a year-on-year turnaround from a net loss to a net profit.

During the reporting period, the company has continued to increase its investment in research and development and innovation. It is strategically focusing on cutting-edge technology platforms such as antibody drugs, ADCs, and mRNA vaccines. The company is also steadily advancing the research and industrialization process of its biopharmaceutical business pipeline. Its product portfolio covers multiple core therapeutic areas, including oncology, metabolism, and autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107941055?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107941055","market":"nz","top_or_hot":-1,"title":"Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss","media":"Stock News","content":"<p><b>Cspc Innovation Pharmaceutical Co., Ltd.</b> (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company between 1.18 billion yuan and 1.36 billion yuan. This represents a year-on-year turnaround from a net loss to a net profit.<br><br>During the reporting period, the company has continued to increase its investment in research and development and innovation. It is strategically focusing on cutting-edge technology platforms such as antibody drugs, ADCs, and mRNA vaccines. The company is also steadily advancing the research and industrialization process of its biopharmaceutical business pipeline. Its product portfolio covers multiple core therapeutic areas, including oncology, metabolism, and autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cspc Innovation Pharmaceutical Co., Ltd.</b> (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company between 1.18 billion yuan and 1.36 billion yuan. This represents a year-on-year turnaround from a net loss to a net profit.<br><br>During the reporting period, the company has continued to increase its investment in research and development and innovation. It is strategically focusing on cutting-edge technology platforms such as antibody drugs, ADCs, and mRNA vaccines. The company is also steadily advancing the research and industrialization process of its biopharmaceutical business pipeline. Its product portfolio covers multiple core therapeutic areas, including oncology, metabolism, and autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0226","symbol_name":"食品制造","start_time":0,"source_url":"","article_id":"1107941055","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107941055","pubTimestamp":1785145095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BK0226":"食品制造"},"translate_title":"石药创新药预计2026年上半年净利润11.18-13.6亿元，同比扭亏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1},"content_text":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company between 1.18 billion yuan and 1.36 billion yuan. This represents a year-on-year turnaround from a net loss to a net profit.During the reporting period, the company has continued to increase its investment in research and development and innovation. It is strategically focusing on cutting-edge technology platforms such as antibody drugs, ADCs, and mRNA vaccines. The company is also steadily advancing the research and industrialization process of its biopharmaceutical business pipeline. Its product portfolio covers multiple core therapeutic areas, including oncology, metabolism, and autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107941055","isCrawlerRequest":true}